Effects of rapamycin on hematopoiesis.
Quesniaux
V F
VF
Sandoz Pharma Ltd, Basel, Switzerland.
Wehrli
S
S
Wioland
C
C
Schuler
W
W
Schreier
M H
MH
D000818:Animals; D001854:Bone Marrow Cells; D002352:Carrier Proteins / Q000378:metabolism; D002455:Cell Division / Q000187:drug effects*; D002460:Cell Line; D002478:Cells, Cultured; D003114:Colony-Forming Units Assay; D004268:DNA-Binding Proteins / Q000378:metabolism; D005260:Female; D006360:Heat-Shock Proteins / Q000378:metabolism; D006410:Hematopoiesis / Q000187:drug effects*; D016298:Hematopoietic Cell Growth Factors / Q000494:pharmacology*; D006412:Hematopoietic Stem Cells / Q000166:cytology* / Q000187:drug effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007378:Interleukins / Q000494:pharmacology*; D051379:Mice; D008810:Mice, Inbred C57BL; D011090:Polyenes / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000494:pharmacology; D020123:Sirolimus; D022021:Tacrolimus Binding Proteins
D002352:Carrier Proteins; D004268:DNA-Binding Proteins; D006360:Heat-Shock Proteins; D016298:Hematopoietic Cell Growth Factors; D007166:Immunosuppressive Agents; D007378:Interleukins; D011090:Polyenes; D011994:Recombinant Proteins; D022021:Tacrolimus Binding Proteins; D020123:Sirolimus